Shield Therapeutics plc
SHIEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.02 | -0.00 | -0.01 |
| FCF Yield | -29.40% | -84.47% | -128.35% | -21.60% |
| EV / EBITDA | -2.40 | -1.77 | -0.77 | -4.00 |
| Quality | ||||
| ROIC | -93.45% | -91.33% | -360.37% | -48.70% |
| Gross Margin | 46.40% | 30.78% | 44.70% | 35.48% |
| Cash Conversion Ratio | 0.25 | 0.87 | 0.45 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 91.97% | 104.99% | -24.06% | 28.31% |
| Free Cash Flow Growth | 77.06% | -98.96% | -7.13% | -1,221.29% |
| Safety | ||||
| Net Debt / EBITDA | -0.93 | -0.21 | -0.13 | 0.64 |
| Interest Coverage | -5.91 | -30.84 | -101.99 | -1,876.64 |
| Efficiency | ||||
| Inventory Turnover | 3.05 | 2.83 | 1.73 | 0.44 |
| Cash Conversion Cycle | 237.38 | 188.48 | 184.03 | -546.59 |